US 7122046

I'll search for this specific patent number across USPTO and CAFC sources.

Summary — US Patent 7,122,046

Source of record: U.S. Patent & Trademark Office data as mirrored on Google Patents, https://patents.google.com/patent/[US7122046](/patent/US7122046)/en (fetched 2026‑09‑26). Unless noted, the bibliographic details below are taken from that record. Where I could not verify something authoritatively, I say so explicitly.

Bibliographic data

Continuity (per the specification's Cross Reference section): This patent is a continuation of Ser. No. 09/815,530 (filed 2001‑03‑23, now US 6,468,295), which is a continuation of Ser. No. 09/434,411 (filed 1999‑11‑04, now US 6,248,084), which is a continuation of Ser. No. 08/965,588 (filed 1997‑11‑06, now US 6,010,527), which is a continuation of Ser. No. 08/342,741 (filed 1994‑11‑21, now US 5,817,145). The 1994 priority date is the basis for the "1994‑11‑21" priority field above.

Caveat on assignee: The patent's own reassignment history shows a chain of security interests (Merrill Lynch Capital, then General Electric Capital Corporation as agent) layered over an ownership transfer to 3M Innovative Properties Company in 2014. Google's "current assignee" listing of "General Electric Co" appears to be an artifact of those security‑interest records rather than a present ownership interest; I cannot resolve this definitively from the materials I retrieved, so treat the 3M attribution as the better‑supported one and the GE listing as unverified.

Abstract

A treatment device having a first portion in a first plane, a treatment portion with a cover in a second plane that defines a treatment volume extending between the first and second planes, and a flexible transition portion connecting the first portion to the treatment portion. The treatment portion includes a polymeric foam ring with interior and exterior walls extending from the first plane to the second plane; the cover spans the interior wall to form a closed treatment volume. The foam ring may be impregnated with a medicament selected from antibiotic, antifungal, antimicrobial, deodorant, and nitric oxide materials. The cover may include a pocket for an accessory such as a heater or a mapping grid. Also claimed are methods of treating a treatment area on a patient's skin using the device, including releasing the medicament into the treatment volume by heating.

Independent claims in plain language

Claim 1 — Device. A treatment device with: (a) an attachment portion lying in a first plane; (b) a cover in a second plane that defines a non‑contact treatment volume over a treatment area; (c) a polymeric foam ring running from the first plane up to the second plane; (d) a flexible transition membrane located outside the foam ring that connects the attachment portion to the cover; (e) the foam ring having interior and exterior walls, each spanning between the two planes; (f) the cover spanning at least the interior wall's distance so as to close off the treatment volume; and (g) a medicament means in the foam ring, formulated to be released into the treatment volume when heat is applied.

Claim 12 — Method of treating a skin area. Using a device with a closed treatment volume, a first portion in a first plane, a treatment portion with a medicament‑impregnated foam ring spanning into a second plane plus a cover in that second plane, and a flexible transition portion joining them, the method comprises: attaching the device to skin so the volume encloses the treatment area; flexing the transition portion to accommodate patient motion; heating the treatment volume; and releasing the medicament into the volume in response to that heat.

Claim 19 — Method of tissue treatment. Using a device defining a medicament‑impregnated treatment volume, the method comprises: attaching the device over but out of contact with the treatment area so the volume encloses it; flexing a transition membrane to accommodate motion; and releasing the medicament into the volume by heating the volume.

Structural notes / observations: The device claims are directed to a closed, non‑contact wound enclosure whose compliance comes from two cooperating mechanisms — the flexible transition membrane (a "pay‑out" pleat/convolution that absorbs shear so the adhesive rim doesn't peel) and the compressible foam ring standoff (which reduces in height as the device stretches, increasing projected transition area). Claim 1 uses "medicament means," a means‑plus‑function‑style limitation that would be construed under 35 U.S.C. § 112(f) against the specification's disclosure (impregnation of the foam with antibiotic/antifungal/antimicrobial/deodorant/nitric‑oxide materials, released on heating). Dependent claims 2–11 add polyurethane or reticulated‑polyurethane foam, a flexible adhesive flange with release liner, and the pocket/heater/passive‑heater/mapping‑grid accessories. One drafting irregularity worth flagging: claims 20–22 depend from claim 19 yet refer to "the cover," while claim 19 itself does not expressly recite a cover — I note this as my own reading of the claim text, not as an adjudicated construction.

Litigation / CAFC 2026 dockets

I searched for the specific number "7122046" / "7,122,046" in connection with Federal Circuit and district‑court activity and found no CAFC 2026 docket, appeal, IPR, or pending litigation naming this patent. The searches surfaced unrelated 2026 Federal Circuit matters (e.g., Yechezkal Evan Spero v. Mercedes‑Benz USA, LLC, Nos. 2025‑1306/1307/1473, Rule 36 affirmance dated 2026‑05‑14, concerning US 10,894,503; and Align Technology v. ClearCorrect, W.D. Tex. No. 6:24‑cv‑00187, decided 2026‑06‑18) — none of which involve patent 7,122,046. That negative result is consistent with the patent's status as fee‑expired since 2016‑10‑01, which would leave it unenforceable as an infringement cause of action in 2026, though I cannot rule out unindexed or unretrieved proceedings.

Confidence levels: Bibliographic data and claim text — high (drawn from the USPTO/Google Patents record and the full specification). CAFC/2026 litigation absence — moderate (based on web searches of public sources, not an exhaustive docket check). Current‑ownership attribution — low‑to‑moderate, for the reasons given above.

I'll search for litigation records involving US patent 7122046.

Let me search dedicated litigation databases.

Summary: No litigation identified for US 7,122,046

Based on my searches of patent-litigation sources (including RPX/Unified Patents-style litigation listings surfaced via web search, CourtListener/Free Law Project dockets, and general web searches keyed to the specific number "7,122,046" and "7122046"), I could not identify any litigation — district court, Federal Circuit, ITC, or PTAB — involving U.S. Patent No. 7,122,046.

I want to be transparent about what this does and does not mean.

What the searches returned

• No district-court complaint, case number, or docket naming US 7,122,046 as an asserted patent was found.
• No CAFC appeal referencing US 7,122,046 was found.
• No PTAB proceeding (IPR/PGR/CBM) naming US 7,122,046 as the challenged patent was found.
• Searches surfaced only the patent's bibliographic record (Google Patents, Radaris inventor listing), the Japanese patent JP 7122046 B2 (an unrelated patent to Chubu University — this is a different jurisdiction and different subject matter, B01J/C07C chemistry, and is not the US patent), and various unrelated litigation documents that merely happened to match the query text.

I did not find any search result that specifically ties US 7,122,046 to a lawsuit. Accordingly, I am not reporting any case and am not going to construct a case list by inference.

Context that bears on the likelihood of litigation

From the authoritative patent text you provided (not from search results):

• Priority date: 1994‑11‑21; filed: 2002‑09‑24; granted: 2006‑10‑17.
• Status: Expired – Fee Related, expires 2016‑10‑01. This means the patent has been expired for roughly a decade, which sharply limits the opportunity for (and incentive to bring) new infringement suits.
• Current assignees: General Electric Co. and 3M Innovative Properties Co.; original assignee Arizant Technologies LLC (which acquired it from Augustine Medical, Inc. in 2004).
• The patent is a continuation in a family that includes US 5,817,145; US 6,010,527; US 6,248,084; US 6,468,295; and US 6,013,097, among others. Family members other than the '046 patent may have been litigated, but I found no evidence tying any such case to the '046 patent itself, and I will not attribute another patent's case to this one.

Caveats / verification steps you should take

This is a negative finding from web-accessible sources, not a complete clearance search. Before relying on it:

1. Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/caselist) — I could not retrieve a specific case for this number; verify by searching the patent number directly in the portal's search field.
2. PACER / CourtListener RECAP — run a docket search for "7,122,046" and "7122046" as the patent-in-suit; my searches did not surface a docket, but PACER is the definitive source for filed complaints.
3. USPTO Patent Center / Assignment records — check the patent's "Assignment" and "Litigation" tabs; the assignment trail you supplied shows only security-interest and ownership transfers (Merrill Lynch, GE Capital, GE, 3M), with no litigation-related assignments.
4. Westlaw/Lexis KeyCite or Docket Navigator — the CRU-style litigation search reports used in reexaminations (as seen in one search hit, for an unrelated patent) are the type of record that would capture litigation on this patent; a commercial database search would confirm.

Bottom line

No known litigation involving U.S. Patent No. 7,122,046 was identified. If your matter requires a definitive answer, I recommend confirming via Unified Patents' portal and PACER/Docket Navigator, since free web search may not index every complaint, and I cannot certify this negative result as exhaustive.

PTAB / AIA Trial Landscape — US 7,122,046 B2 ("Treatment device")

Sources used: the structured "PTAB proceedings on file" block (canonical USPTO Open Data Portal list, supplied in the prompt) and targeted web searches for IPR/PGR/CBM records naming this patent or its owners (Arizant Technologies LLC → 3M Innovative Properties Co.; General Electric listed as a current assignee). The patent text and bibliographic data are from https://patents.google.com/patent/US7122046/en.

Proceedings overview

Total AIA trial proceedings on file: zero. The ODP structured block reports no AIA trial proceedings for US 7,122,046 as of the most recent ingest, and my independent searches identified no IPR, PGR, or CBM petition ever filed against it — so the breakdown is 0 active / 0 instituted / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denials, and the bottom-line defensive posture does not rest on any PTAB outcome at all: the patent expired on 2016-10-01, which is a far stronger defense than any FWD could have given a defendant (see Strategic summary).

No proceedings to report

There is no proceeding number, petitioner, panel, institution decision, Final Written Decision, settlement, or Federal Circuit appeal to itemize. I will not manufacture one. Search noise to be aware of, so nobody repeats my error:

• US 8,717,204 (Realtime Data) — a different patent, repeatedly hit when searching "204 IPR."
• JP 7122046 B2 — a 2022 Japanese grant for an amide-production catalyst; a Japanese registration number that coincidentally matches this US number. Unrelated.
• The Ericsson/Nokia/AT&T/T-Mobile/Verizon petition hits are directed to a different '204 family (a 2017-issued patent) and have nothing to do with US 7,122,046.

Confidence note: I can state with high confidence that no AIA trial proceeding is indexed for this patent. I cannot prove a universal negative — a pre-2012 interference or a paper-filed challenge outside the AIA trial regime would not appear in the ODP AIA-trial field, and my web search is not an exhaustive docket search. If this matters to a live matter, the belt-and-suspenders check is a party-name query in PTAB E2E (https://ptacts.uspto.gov/ptabweb/) and Patent Center (https://patentcenter.uspto.gov/) for "Arizant Technologies," "Augustine Medical," and the application number 10/254,175.

Strategic summary

Claim status. All 25 claims stand as issued — none is canceled, because no trial ever reached a Final Written Decision. Claims 1–11 are apparatus claims (claim 1 being the independent apparatus claim reciting the attachment portion, cover in a second plane, polymeric foam ring, flexible transition membrane, closed treatment volume, and "a medicament means in the polymeric foam ring for being released into the treatment volume by the application of heat"); claims 12–18 are method-of-treating claims and claims 19–25 are method-of-tissue-treatment claims, each independently recited. Nothing is canceled; nothing is adjudicated; everything is simply untested at the PTAB. The more consequential fact from the same Google Patents record is the status line: Expired – Fee Related, adjusted expiration 2016-10-01. With a 1994-11-21 priority date and a 2002-09-24 filing date, the enforceable term ran out roughly a decade ago.

Estoppel landscape. § 315(e)(2) estoppel is a non-issue: estoppel attaches only to petitioners who reach a Final Written Decision, and there has never been one. Practically, that means there is no estoppel bar on any prior-art ground for anyone. But the corollary is that the whole IPR toolkit buys nothing you don't already have: there is no FWD to point to, no canceled claim to wave at a plaintiff, and no institution record to pressure a settlement. A defendant's validity position has to be built from scratch in district court under §§ 102/103/112 (pre-AIA §§ 102/103, given the 1994 priority date), and the art cited on the face of the patent and in the family's prosecution is fair game without restriction.

Pattern signals. No repeat petitioner, because there is no petitioner. No defensive aggregator (Unified Patents or similar) appears anywhere in the family record — if a coordinated validity challenge had been run against this wound-treatment family, it would show in the "Cited By"/proceeding data and it does not. The only appellate history attached to this family in my search results is pre-AIA district-court litigation over different Augustine patents — the convective-warming-blanket patents (the '188, '102, '320, '371 line) in Augustine Medical, Inc. v. Gaymar Industries, 181 F.3d 1291 (Fed. Cir. 1999), and Augustine Medical, Inc. v. Progressive Dynamics, Inc. (Fed. Cir. 1999), which turned on a broad settlement-and-release and on CIP priority for "self-erecting" blankets. Do not attribute either holding to US 7,122,046; they are different patents, different claim language, and different technology. I found no Federal Circuit appeal involving 7,122,046 itself.

Recommended next steps

1. Lead with expiration, not with PTAB. For any assertion today, the first question is what damages window exists. Under 35 U.S.C. § 286, recovery reaches back only six years from the complaint; for a complaint filed in 2026, that reaches back to roughly 2020 — entirely after the 2016-10-01 expiration in the Google Patents status record. That combination typically leaves no recoverable pre-expiration damages absent unusual tolling facts (e.g., prior suits in the chain). Get the certified term/expiration record from Patent Center (application 10/254,175) and confirm the expiration date against the maintenance-fee and any terminal-disclaimer events before anyone builds a damages model.
2. Verify no live family member is being asserted instead. This patent is one of eight family applications (including US 5,817,145; US 6,010,527; US 6,248,084; US 6,468,295; US 6,293,917; US 6,013,097; and abandoned US 2002/0026133). Assertion letters in this space often pivot to siblings or to the later Arizant/3M continuation patents (e.g., the "minimal contact" and extremity-treatment devices). Confirm the exact patent number on the face of any demand letter rather than assuming a family match.
3. If you nonetheless want a PTAB filing on the record: an IPR is only available against a patent that has not expired; you cannot IPR an expired patent (the Board will not institute where no claims remain amendable/patentable — and there is no live claim scope to cancel). For expired patents, the validity vehicle is a district-court declaratory-judgment action or an invalidity defense under pre-AIA §§ 102/103/112. Note for the file that claim 1's "medicament means … for being released … by the application of heat" limitation is drafted in classic means-plus-function form and will invite a § 112(f) / Williamson construction fight over what structure the specification discloses for "released by the application of heat" — my own observation from the claim text, not from any proceeding.
4. Because there is no PTAB record to link, link the primary sources instead: the patent itself and its full claim set at https://patents.google.com/patent/US7122046/en; PTAB E2E at https://ptacts.uspto.gov/ptabweb/ for the negative-search confirmation; Patent Center at https://patentcenter.uspto.gov/ for the term and fee history. If a proceeding surfaces on further docketing that the ODP ingest missed, I would flag it immediately — but on the record in front of me, the correct answer is: no AIA trial activity on file, and the patent is expired.

I'll research the assignment chain for US 7,122,046. Let me run several targeted searches.

Let me try to pull the reel/frame data and correspondent information directly.

Assignment & Ownership Reconstruction — US 7,122,046

Important methodological caveat up front. I was unable to open USPTO Patent Assignment Search directly. assignmentcenter.uspto.gov and assignment.uspto.gov/patent/index.html are JavaScript applications that my web tooling cannot render, and targeted searches for the reel/frame strings returned nothing. The timeline below is therefore built from the USPTO-sourced reassignment entries mirrored in the Google Patents legal-events record for this patent (the authoritative text supplied with this task), supplemented by press coverage. I could not retrieve reel/frame numbers, execution dates, or correspondent-of-record for any entry. I am not going to invent reel/frame numbers. Every reel/frame slot below is marked as unretrieved and should be verified at the Assignment Center before this analysis is relied on.

Inventors

Pattern notes (flagging, not findings):

• No classic "inventor exodus" signal relative to the original 1994 filing. The original application in this chain (Ser. No. 08/342,741) was filed 1994‑11‑21, and Augustine remained CEO of the Augustine Medical/Arizant organization until he left in 2002 — roughly eight years post-filing, so there is no within‑12‑months departure that would suggest a portfolio dump.
• A departure does, however, line up with the 2002 continuation. This application (10/254,175) was filed 2002‑09‑24, and press coverage reports Augustine left Arizant in 2002 after a dispute (Gilman & Bedigian; MedCity News). So the continuation was filed in the same window in which the founder and lead inventor was exiting. That is a legitimate thing to note, but it is not a fire-sale indicator here — the company kept the patent family and continued prosecuting it (see timeline). I could not determine departure dates for Arnold, Hamlin, or Stapf.

Original assignee

Arizant Technologies LLC (Eden Prairie, MN) is the assignee named on the face of the issued patent. Two qualifications:

1. At the 2002 filing the applicant was almost certainly Augustine Medical, Inc. The rights moved to Arizant Technologies LLC by the recorded assignment of 2004‑05‑26 (assignor: Augustine Medical, Inc.), which is why the issued 2006 patent names Arizant. Arizant Technologies LLC appears to be the IP-holding affiliate of the Arizant group rather than the sales entity.
2. Primary line of business / products: Arizant was the maker of the Bair Hugger forced-air patient-warming system — a real, shipped, hospital-market product line. This is a genuine operating company, not a licensing vehicle.
3. Current status: Acquired. 3M announced the purchase of Eden Prairie–based Arizant Inc. for ~$810 million in September 2010 and the deal closed in 2010 (MedCity News; MassDevice; AP). Arizant's products were folded into 3M's Health Care business, and the patent family was later recorded to 3M Innovative Properties Company.

I could not independently verify Arizant's pre‑2010 capital structure or whether Arizant Inc. was ever publicly listed, so I make no claim on that point.

Assignment timeline

Recording dates below are taken from the Google Patents legal-events record. Execution dates and reel/frame are unretrieved for every entry. Conveyance types are quoted from the USPTO record.

For each entry: YYYY‑MM‑DD (recorded) — Reel not retrieved

1. 2004‑05‑26 — Reel not retrieved (verify at Assignment Center)

   • Conveyance: Assignment of assignors' interest ("see document for details")
   • Assignor: Augustine Medical, Inc.
   • Assignee: Arizant Technologies LLC
   • Correspondent: not retrieved
   • Context: Internal reorg / acquisition cleanup — the Augustine Medical operating business (and its patent family) was rolled into the Arizant organization; this is why the 2006 patent issues under the Arizant name.

2. 2004‑08‑01 — Reel not retrieved

   • Conveyance: Security interest
   • Assignor: Arizant Technologies LLC
   • Assignee: Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., as Agent
   • Correspondent: not retrieved
   • Context: Securitization / acquisition financing — recorded ~2.5 months after the Arizant restructuring; consistent with secured lending against the IP as collateral. Not an ownership transfer.

3. 2009‑06‑11 — Reel not retrieved

   • Conveyance: Security agreement
   • Assignor: Arizant Technologies LLC
   • Assignee: General Electric Capital Corporation, as Administrative Agent
   • Correspondent: not retrieved
   • Context: Securitization (refinancing) — a new security interest layered on, presumably replacing the Merrill Lynch facility.

4. 2009‑06‑12 — Reel not retrieved

   • Conveyance: Release by secured party
   • Assignor: GE Business Financial Services Inc. (f/k/a Merrill Lynch Business Financial Services Inc.), as Administrative Agent
   • Assignee: Arizant Technologies LLC
   • Correspondent: not retrieved
   • Context: Securitization unwind — release of the 2004 Merrill Lynch lien. The "f/k/a" tells the story: GE Capital acquired Merrill Lynch's commercial-finance lending business, so the same lender releases under a new name. This is a lender chain, not an NPE chain.

5. 2010‑10‑14 — Reel not retrieved

   • Conveyance: Recorded as "Assignment of assignors' interest"
   • Assignor: Arizant Technologies LLC
   • Assignee: General Electric Capital Corporation
   • Correspondent: not retrieved
   • Context: Securitization, mis-recorded — see the correction at #6.

6. 2010‑12‑06 — Reel not retrieved

   • Conveyance: Corrective assignment — expressly "to correct the nature of the conveyance as a release by secured party, and the identity of the assignor and assignee previously recorded"
   • Assignor: General Electric Capital Corporation, as Administrative Agent
   • Assignee: Arizant Technologies LLC
   • Correspondent: not retrieved
   • Context: Securitization unwind / record correction — the 2010‑10‑14 entry was not an ownership transfer. GE Capital was releasing its lien, timing that coincides with 3M's October 2010 acquisition of Arizant (repayment of the secured facility on change of control). Inference on my part — the corrective-assignment text is the evidence; the acquisition timing is the explanation.

7. 2014‑01‑16 — Reel not retrieved

   • Conveyance: Assignment of assignors' interest
   • Assignor: Arizant Technologies LLC
   • Assignee: 3M Innovative Properties Company
   • Correspondent: not retrieved
   • Context: Defensive aggregation / corporate IP consolidation — post-acquisition formalization of title into 3M's IP-holding affiliate. This is the terminal link in the chain.

Additional event (not an assignment): adjusted expiration 2016‑10‑01, legal status Expired – Fee Related.

Cross-check against the prior section of this analysis: the earlier-generated summary flagged Google's "Current Assignee: General Electric Co." listing as an artifact. This timeline confirms that reading: GE Capital's two appearances are a security agreement (#3) and a mis-recorded entry subsequently corrected to a release (#5/#6). Neither is an ownership interest. 3M Innovative Properties Company is the better-supported owner.

Timeline diagram

timeline
    title Ownership of US 7122046
    1994 : Original app filed by Augustine Medical
    2002 : Continuation filed as 10/254175
    2004 : Rights assigned to Arizant Technologies LLC
         : Merrill Lynch security interest recorded
    2006 : Patent US7122046 issues
    2009 : GE Capital security agreement recorded
         : Merrill Lynch lien released by GE affiliate
    2010 : GE entry recorded as assignment
         : Corrected to release by secured party
         : 3M acquires Arizant Inc for 810M
    2014 : Arizant assigns to 3M Innovative Properties
    2016 : Patent expires for fee non-payment

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The final assignee, 3M Innovative Properties Company, does bear an "IP"-style name, but it is a wholly owned IP-holding affiliate of 3M Company (NYSE: MMM), a ~$30B+ diversified manufacturer that ships the acquired Bair Hugger and wound-care product lines. No single-purpose Delaware/Texas shell, no registered-agent-only address, no licensing-only entity appears anywhere in the chain (recordings #1, #7). Post-issuance transfers are two lenders and one corporate parent — the opposite of a shell cascade.

2. Known asserter in the chain — not present. None of the recorded assignees — Augustine Medical, Inc.; Arizant Technologies LLC; Merrill Lynch Capital; GE Capital / GE Business Financial Services; 3M Innovative Properties Company — appears on the Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, or Spangenberg rosters. GE Capital appears only as a secured creditor, never as owner.

3. Repeat correspondent across the chain — unclear (data gap). I could not retrieve the correspondent-of-record for any of the seven recordings, and I found no indexed page exposing those fields. This is the single most important thing to check at the Assignment Center, because it is the field the task correctly identifies as the cleanest repeat-player tell. I have no evidence either way and am not going to characterize it.

4. Cascading transfers through chained LLCs in <24 months — not present. There is a dense cluster — four recordings between 2009‑06‑11 and 2010‑12‑06 — but these are a security agreement, its companion release, one mis-recorded lien entry, and the corrective assignment that fixed it, all involving the same two parties (Arizant and GE Capital as agent). That is a lender-relationship churn, not an LLC hopscotch. The only genuine ownership change in that window is 3M's acquisition of Arizant by public cash deal.

5. Pre-litigation transfer — not present / not applicable. I found no infringement suit, IPR, or CAFC appeal naming US 7,122,046, consistent with the prior section's search. The nearest litigation the family touches is In re Bair Hugger Forced Air Warming Devices Products Liability Litigation, MDL No. 15‑2666 (D. Minn.), where 3M/Arizant are defendants on product-liability theories — not a patent assertion. I cannot rule out an unindexed assertion, but nothing supports a transfer-timed-to-suit theory.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 proceeding for Arizant or Augustine Medical surfaced. Arizant exited via a ~$810M cash acquisition by 3M announced September 2010 — the opposite of a distressed sale. Note the founder's separate 2004 federal plea and $2M fine (MedCity News; AP) involved Augustine personally and did not put this patent family into an estate.

7. Privateering — not present. No evidence that 3M transferred this family to an NPE to assert against competitors. The recorded movement runs into 3M, not out of it.

8. Defensive aggregator — not present, with a caveat. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN; it terminates at an operating company's IP affiliate. However, the practical outcome is neutralization by a different route: the patent expired for failure to pay maintenance fees with an adjusted expiration of 2016‑10‑01, leaving nothing to assert. That is abandonment, not defensive aggregation — I list it as a fact, not as a signal hit.

Verdict

Defensive / non-asserting — with a stated taxonomy caveat.

The chain terminates at 3M Innovative Properties Company per the assignment recorded 2014‑01‑16 from Arizant Technologies LLC, i.e., an IP-holding affiliate of a large operating company rather than a defensive aggregator — so the parenthetical in the label ("chain terminates at a defensive aggregator") does not literally apply; I am using the label for its non-asserting half. The two intervening ownership events are actually security interests (Merrill Lynch, recorded 2004‑08‑01; GE Capital, recorded 2009‑06‑11) plus a mis-recorded entry that was correctively converted into a release on 2010‑12‑06, none of which is an NPE transfer. Combined with zero identified assertions of the '046 patent and a 2016‑10‑01 fee-expiry, there is no NPE pattern and, in 2026, no enforceable right to assert.

To be verified before this is relied on: reel/frame, execution dates, and correspondent-of-record for all seven recordings — the last being the decisive data point I could not obtain.

• USPTO Assignment Center: https://assignmentcenter.uspto.gov/
• Alternate interface: https://assignment.uspto.gov/patent/index.html
• Record of the legal events used above: https://patents.google.com/patent/US7122046/en

I'll search for the patent record and its cited prior art.

Let me retrieve the Reference-Cited front matter and verify key references.

Let me try to complete the cited-reference list for the '046 patent itself.

Prior Art Analysis — US 7,122,046 B2 ("Treatment device")

Analyst note on scope. The previously generated sections (patent summary, litigation summary) remain accurate for the bibliographic and claim data, and I found nothing in this pass that contradicts them. This section builds on them and does not repeat the claim text or bibliographic table. It adds the citation-level prior-art analysis requested.

Patent verified literally: US 7,122,046 B2, "Treatment device," App. No. 10/254,175, filed 2002‑09‑24, granted 2006‑10‑17, priority 1994‑11‑21, 25 claims (independent 1, 12, 19). Source: https://patents.google.com/patent/US7122046/en.

1. What constitutes "the citations for 7122046," and a completeness caveat

The '046 record carries 94 cited references (Google Patents "Citations (94)"), comprising the front-page "(56) References Cited" list plus any third-party submissions. The authoritative text supplied to me truncates that list mid-entry at US 4,969,881 — I captured 66 entries verbatim (US 222,690 through US 4,969,881). I did not retrieve the remaining ~28 entries for the '046 record itself, and I will not pad the list by inference from sibling patents.

What the '046 front page confirms directly (from the patentimages PDF snippet I retrieved, https://patentimages.storage.googleapis.com/d5/68/71/a5e344da28599b/US7122046.pdf):

• (56) References Cited — U.S. Patent Documents beginning "222,690 A 12/1879 Goldschmidt (Continued)"; Foreign Patent Documents beginning "CH 269938 7/1950 (Continued)"; Other Publications — "U.S. Appl. No. 10/246,605, filed Sep. 17, 2002, Augustine."
• Primary Examiner: Robert L. Nasser; Attorney/Agent: Incaplaw; Terrance A. Meador.

⚠️ Flag: any complete 94-item list used for a validity opinion should be taken from the patent's own front page (USPTO Patent Center / the granted PDF), not from this reconstruction. The table below is the verified subset.

2. Legal framework applied (pre-AIA, because the application was filed 2002‑09‑24)

• All cited documents are dated well before 1994 (the earliest claimed priority), so they are § 102(a)/(b) art on any priority theory — except where noted.
• Claim 1 requires all of: attachment portion in a first plane; cover in a second plane defining a non‑contact volume; a polymeric foam ring with interior and exterior walls spanning the two planes; a flexible transition membrane located outside the foam ring; the cover spanning the interior wall to make a closed volume; and a "medicament means" released into the volume by application of heat.
• Accordingly, a cited reference anticipates under § 102 only if it discloses every one of those elements as arranged. Where a reference discloses a structural subset, its realistic role is § 103 combination art. I state which is which below. Confidence in mapping: moderate — I have the reference titles/dates from the record but have not read each reference's full specification, so the claim mapping is a screening result, not a final anticipation determination.

3. Verified cited patent documents (66 entries), grouped by the claim element they bear on

Dates are given as the record shows them: priority/filing date → publication date.

3A. Wound shields / non-contact cavity coverings — target claim 1 (elements a, b, f) and claim 13 (transparent cover)

3B. Ring / distancer / standoff structures — target claim 1(c), 1(d), 1(e); claims 2–3 (foam chemistry)

3C. Polymeric foam / foam-layer dressings — target claim 1(c), claims 2–3, and the foam sub-structure of claim 19

3D. Heating (active and passive) — target claims 8, 12, 15, 17, 19, 24

3E. Drug / medicament delivery to skin — target claim 1(g) "medicament means", claims 12, 18, 19, 25

3F. Compliance / expansion / attachment mechanics — target claim 1(d), claims 4–6, and the method steps of claims 12 and 19

Remaining verified entry: US 4,969,881 A (1989 priority) — the truncated entry (assignee/date cut off in my source). The sibling record US 5,817,145 identifies US 4,969,881 as "Disposable hyperbaric oxygen dressing" (Viesturs) — a controlled-atmosphere dressing. If that identification holds for the '046 citation (⚠️ verify against the '046 front page), its candidate claims are 1(b), 1(f), 12, 19 (closed volume with a controlled internal atmosphere).

4. The single most probative non-structural citation: FR 1,527,887 (Veilhan)

The '046 specification as supplied does not name Veilhan. However, the immediately related family application US 2002/0026133 A1 (Ser. No. 09/880,373, filed 2001‑06‑13, published 2002‑02‑28) states: "Although some forms of wound heaters and non-contact wound coverings are known from Veilhan Fr. 1,527,887 (1969) they are not generally accepted…" (https://uspto.report/patent/app/20020026133). That is an express applicant admission that non-contact wound coverings with heaters were known from Veilhan. Because the '046 patent claims the same family, FR 1,527,887 is the reference most likely to be used to frame § 103 combinations against claim 1's enclosure + heat architecture. Flag: this admission is in the sibling application's text, not verbatim in the '046 grant as supplied to me — verify in the '046 specification before relying on it.

5. Non-patent citation in the record

• "U.S. Appl. No. 10/246,605, filed Sep. 17, 2002, Augustine" — listed under "(56) OTHER PUBLICATIONS" on the '046 front page. This is a co-pending Augustine application filed one week before the '046 application; it is a § 102(e)/double-patenting-type citation, not a § 102(a)/(b) printed publication against the 1994 priority. It should be treated separately from the pre-1994 art.

6. References I could not verify as '046 citations (likely completing the 94 — verify before use)

The sibling front pages in the same family (notably US 6,010,527, https://uspto.report/patent/grant/[6010527](/patent/6010527), and US 5,817,145) list additional documents that plausibly complete the '046 list. I present them as unverified for '046: US 5,003,971 (Buckley, "Expansion system for a medical and surgical dressing," 1991‑04‑02), US 5,025,777 (Hardwick, "Chemically heated blanket," 1991‑06‑25), US 5,066,? (Farnsworth II), US 5,086,763 (Hathman, "Protective reclosable wound dressing," 1992‑02‑11), US 5,107,832 (Guibert, "Universal thermotherapy applicator," 1992‑04‑28), US 5,145,? (Krueger, 1992‑09‑08), US 5,170,781 (Loomis, 1992‑12‑15), US 5,190,031 (Guibert, 1993‑03‑02), US 5,230,350 (Fentress, 1993‑07‑27), US 5,602,? / US 5,609,619 (Pompei, "Method and apparatus for heating bodies," 1997‑03‑11), US 5,662,624 (Sundstrom, "Heat dressing comprising a heat generating unit and an adhesive layer," 1997‑09‑02), US 5,531,670 (Westby, "Heat conserving bandage"), US 5,431,622 (Pyrozyk, "Thermal bandage"), plus foreign documents EP 0 424 165 A1, EP 0 485 657, GB 2,261,822, and WO 94/00090.

Most notable of these, if confirmed: US 5,003,971 (Buckley) — "Expansion system for a medical and surgical dressing" — is the type of reference that would bear directly on claim 1(d) and the "pays out material / increased projected area" limitation; and WO 94/00090 (Augustine) shares a common inventor.

7. Anticipation assessment by claim

Bottom line for § 102: On the 66 verified citations, claims 1, 12, 18, 19 and 25 are not anticipated — the "medicament means in the polymeric foam ring, released into the treatment volume by application of heat" limitation (claim 1(g)) plus the transition membrane located outside the ring arrangement have no evident counterpart in the cited pre-1994 art. The cited art is much stronger as § 103 combination material (e.g., Spangler's transparent non-contact cover + Kendall's foam backing + Checconi/Sarason distancer + Wilson's drug delivery). The dependent claims most exposed to standalone § 102 attack are 4–6, 7, 8, 10, 13, 15, 17, 20, 22, 24.

8. A legal nuance the earlier sections did not address: the family is the closest art — and is probably not § 102 art

The nearest disclosures to '046 are its own predecessors: US 5,817,145 (App. 08/342,741, filed 1994‑11‑21, issued 1998‑10‑06), US 6,010,527 (filed 1997‑11‑06, issued 2000‑01‑04), US 6,013,097 (PCT filed 1995‑11‑21, issued 2000‑01‑11), US 6,248,084 (filed 1999‑11‑04, issued 2001‑06‑19), and US 6,468,295 (filed 2001‑03‑23, issued 2002‑10‑22 — the immediate parent). US 5,817,145 already discloses the attachment portion/first plane, standoff to a second plane, transition portion, closed non-contact volume, foam ring standoff, and a pocket for a planar heater; US 6,468,295's abstract expressly recites "an absorptive foam ring … has in it a medicament selected from the group including an antibiotic material, an antifungal material, and an antimicrobial material."

However, because the '046 application is a straight continuation chain with the same inventive entity (Augustine, Arnold, Hamlin, Stapf) and a common 1994‑11‑21 priority claim, these siblings are ordinarily not "by another" and therefore not pre-AIA § 102(a) or § 102(e) prior art against '046 — they become § 102 art only if a given claim is held not entitled to the earlier chain date (in which case US 6,468,295 and US 6,248,084, published/granted before the relevant date, become the operative references). ⚠️ This is the highest-value issue in any validity analysis of this patent, and it turns on a § 112 written-description/enablement analysis I cannot complete from the record alone.

9. Confidence and verification steps

• Citation identity, dates, and titles for the 66 captured entries — high (taken from the record supplied, cross-checked against the '046 PDF front page and the sibling US 6,010,527 / US 5,817,145 front pages).
• Completeness of the 94-item citation set — low; the source truncated at US 4,969,881. Retrieve the granted PDF's front page or the Patent Center "References Cited" tab.
• Claim-by-claim § 102 mapping — moderate/low; derived from titles and known subject matter, not from reading each reference's disclosure. Each mapped reference must be read before any anticipation conclusion is asserted.
• "No mapping grid in the cited art" — moderate; based on titles only.
• Veilhan admission — moderate; it appears in the sibling application US 2002/0026133 A1, not in the '046 text supplied.
• No litigation involving US 7,122,046 was identified in this pass, consistent with the earlier litigation section; the patent's fee-related expiration on 2016‑10‑01 remains the key context.

Recommended next step: pull the granted PDF front page for the complete 94-item list, then read in full the eight references flagged in bold above (US 2,443,481; US 4,399,816; GB 288,220; WO 89/04158; US 4,341,209; US 2,573,791; US 4,962,761; US 3,608,549) and, if confirmed in the list, US 5,003,971 — these are the references with the most § 102/§ 103 purchase on independent claims 1, 12 and 19.

I'll ground this analysis in the prior art actually listed on the patent page. Let me verify the disclosures of the key cited references rather than relying on titles alone.

Preliminary notes before the analysis

Two flags up front, per the operating rules:

1. Date conflict in the instructions. The task header states "Current Date: April 26, 2026," while the session metadata states today is 2026‑09‑28. I am not resolving this silently — the earlier sections in this file are dated 2026‑09‑26/27, so the April 26 date in the task header appears to be stale boilerplate. Nothing in the §103 analysis below turns on the difference, but the dates of record should not be taken from the task header.
2. Scope of my prior‑art universe. Per the instruction, I am working from the "Prior Art" material on the patent page — i.e., the Citations (94) block (backward citations = prior art of record) and the Families Citing this family (189) block (forward citations). I explicitly exclude the forward citations as anticipatory art (they post‑date the 1994‑11‑21 priority) and exclude the family itself. Where I could not verify a reference's actual disclosure, I say so rather than paraphrasing a title as if it were a holding.

1. Framework and the critical date

Governing law. The application was filed 2002‑09‑24, but the claims are supported by the 1994‑11‑21 disclosure (the specification's own text recites the medicament‑in‑foam and heat‑release limitation verbatim — "A medicament with which the foam ring is impregnated may be released into the wound treatment volume by the application of heat to the wound treatment volume"). The application therefore predates the AIA's first‑inventor‑to‑file provisions, and pre‑AIA 35 U.S.C. §§ 102/103 govern. Assessment follows Graham v. John Deere Co., 383 U.S. 1 (1966), as refined by KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007).

Critical date. With an effective filing date of 1994‑11‑21, the pre‑AIA § 102(b) critical date is 1993‑11‑21. Every reference in the Citations (94) block is dated 1990 or earlier (latest entries: US 4,961,761 Golden, 1990‑10‑16; US 4,947,842, 1990‑08‑14; US 4,890,608, 1990‑01‑02). That is a materially important point: the entire cited art is § 102(b) art, so (i) no Rule 131 swear‑behind is available, and (ii) the § 103(c) common‑ownership carve‑out for § 102(e)/(f)/(g) art does not reach it.

One exception and one trap worth separating out:

• US 4,572,188 (Augustine, granted 1986‑02‑25, "Airflow cover for controlling body temperature") is listed in the Citations block and is squarely § 102(b) art, notwithstanding that it names the same inventor as the '046. A § 102(b) patent is prior art against its own inventor, and § 103(c) does not remove § 102(b) art. This is the single most awkward reference on the face of the patent for the applicant's own family.
• The 1992‑priority Augustine family members (US 5,954,680; 5,964,723; 5,986,163; 6,406,448; 6,465,708; 7,928,281 — all with a 1992‑06‑19 priority listed on the page) appear in the forward‑citing block, but their 1992 priority pre‑dates the '046's 1994 priority. As potentially § 102(e) art they would be removable from the § 103 combination under pre‑AIA § 103(c) if commonly owned at the time of invention. I flag this as a real issue to check, not as a settled point — I have not verified the inventorship/ownership overlap from primary assignment records.

Presumption of validity. Under 35 U.S.C. § 282 the issued claims carry a presumption of validity; a challenger must prove invalidity by clear and convincing evidence. The analysis below is a prima facie case framework, not an adjudication.

Means‑plus‑function. Building on the construction note already in this file: claim 1's "medicament means in the polymeric foam ring for being released into the treatment volume by the application of heat" is in classic § 112 ¶ 6 form. Its scope is limited to the structures disclosed in the specification for performing that function — i.e., a foam impregnated with an antibiotic, antifungal, antimicrobial, deodorant, or nitric‑oxide‑releasing material, plus equivalents. Two consequences: the limitation is narrow, and the recited function (release on heating) can be met inherently by a prior‑art combination that heats an impregnated foam in a closed volume, even if the reference does not describe the release as a designed feature. In re Schreiber / In re Swinehart inherency principles apply.

2. What the cited art actually discloses (verified vs. title‑only)

I verified the following against the references themselves (via Google Patents / Espacenet / the printed specifications):

References I could not verify and therefore will only use as corroborating, title‑level art (flagged each time): US 4,392,816 (Spangler, "Wound protector with transparent cover"); US 4,277,255 (Taylor, "Localized body heat applicator device"); US 3,613,238 (US HEW, "Wound infection prevention device"); US 3,782,377 (Illinois Tool Works, "Sterile plastic shield"); US 697,637 (Lee, "Shield for vaccinations"); US 720,812 (Johnson, "Vaccination‑shield"); US 2,221,758 (Elmquist); US 2,579,791 (Howells, "Heat applying bandage"); US 4,890,608 (Squibb); and US 4,947,842 (Medical Engineering & Development Institute, "Method and apparatus for treating tissue with first and second modalities"). On the last one, the title suggests a multi‑modality tissue‑treatment apparatus and it is the most attractive candidate for the heat/agent‑release limitation — but I could not confirm its disclosure and I will not assert what it teaches. Verify before relying on it.

Note also the applicant's own admission in the '046 background: "Although wound heaters and non‑contact wound coverings are known they are not generally accepted for several reasons," followed by the admission that rigid enclosures "forming a cavity that covers the wound" were adhesively attached. That is an applicant admission usable as prior art for the proposition that both the non‑contact enclosure and the wound heater were known elements.

3. Claim 1 — element‑by‑element mapping

Observation: limitations (a)–(f) are each disclosed, and the combination of (a)–(f) is essentially Checconi's Figure 6 embodiment read with claims 6 and 8 — a plaster‑attached, closed, non‑contact protection volume bounded by a foam distancer and a cover, with a folded/curvable one‑piece wall providing the compliant connection. The only limitation requiring cross‑reference to a different field (thermal treatment) is (g). That is where the § 103 case lives or dies, and I address it separately rather than burying it.

4. The principal obviousness combinations

Combination A — Checconi as the primary reference

WO 1989/004158 (Checconi) in view of US 3,814,095 (Lubens) and US 4,961,761 (Golden).

• Checconi supplies every structural limitation of claim 1 except a heat‑triggered medicament release, and expressly frames the invention around the same problem the '046 recites as its own: preventing the dressing from sticking to the wound and avoiding "painful consequences for the patients and delays in the healing process" (i.e., the "gauze can adhere to the wound area interfering with the healing process" problem in the '046 background).
• Lubens supplies the medicated carrier within a ring‑shaped occlusive body and, critically, the motivation for controlled release: it teaches that effectiveness "depends on … an occlusive dressing" and that pressing the assembly against the skin "increases the rate of skin penetration by the anesthetic agent." A skilled artisan reading Lubens is taught that the release/penetration rate of an agent held in contact with the treatment area is an adjustable process variable affected by the dressing's physical environment.
• Golden supplies the thermal element, including a flexible fluid‑channeled or thermoelectric pack that "readily conforms to the exact contour of the body portion," and even teaches a pocket into which a thermal insert is placed — directly on point for claim 7.

Motivation to combine: All three are in the same field of endeavor (wound/lesion dressings and localized thermal treatment of body surfaces; USPTO classes A61F 13/00 and A61F 7/00, which the '046 itself is classified under). The '046's own background admits wound heaters and non‑contact coverings were both known. The '046 identifies the prior art's own unmet need — "prior art heated bandages which rely on a non‑contact enclosure may use point source type heaters which result in variations in radiant heat flux" — which supplies precisely the reason a skilled artisan would add a conformable, area‑distributed thermal element to Checconi's enclosure. Under KSR, "if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious."

Combination B — Sene as the primary reference

US 2,443,481 (Sene) in view of US 4,341,209 (Schaar), US 4,961,761 (Golden), and US 4,572,188 (Augustine).

• Sene supplies the non‑contact transparent dome, the adhesive flange, the compliance‑providing folded edges/tongues, the closed volume, and — importantly — a manufacturer‑supplied medicament pathway: slits "adapted to allow … the introduction of antiseptic and healing agents," plus an "absorbent removable substance" carried in the body.
• Schaar supplies the express rationale for substituting a polymeric foam body for Sene's rigid shell: foam gives "superior smoothness, flexibility, conformability and softness" as a backing for an adhesive dressing. This is the "substitution of one known element for another to obtain the anticipated result" rationale.
• Golden supplies the heater; US 4,572,188 (Augustine) supplies an airflow/thermal cover controlling the temperature of an enclosed body region — and, being § 102(b) art against the applicant, it is not removable by common ownership.

Motivation to combine: Each reference addresses a recognised deficiency the '046 itself recites — Sene's rigidity (checconi/Sene shells "peel‑off of the patient's skin" upon motion — the '046 background's exact complaint), the lack of thermal control ("This traditional form of bandage does not control the thermal environment of the wound"), and the desire for a conformable, motion‑tolerant dressing. A person of ordinary skill would combine a foam standoff with a transparent non‑contact dome and a conformable heat source because the references teach that each addresses a distinct, known problem in the same device, with predictable results.

Combination C — the non‑contact‑shield line + thermal line

US 697,637 / US 720,812 (vaccination shields) or US 3,613,238 (wound infection prevention) or US 3,782,377 (sterile plastic shield) in view of US 3,814,095 (Lubens) and US 4,961,761 / US 4,846,176 (Golden).

This is the "old and well‑known element" route. Non‑contact shields over a wound with an adhesive periphery are nineteenth‑ and early‑twentieth‑century technology (US 697,637, 1902; US 720,812, 1903; US 222,690, 1879). Lubens adds the ring body plus medicament and the penetration‑rate teaching; Golden adds the heater. Because the shield line is the oldest element, this route is more vulnerable to the argument that the specific combination is not suggested — I offer it as a secondary theory, and note that I have only titles, not confirmed disclosures, for the shield references.

5. Dependent claims 2–11

These are, collectively, the easiest part of the patent for a challenger:

Caveat on claims 2–3: the specification touts tailored "absorbency" and medicament‑impregnation properties for the foam. If the patentee produced unexpected‑results evidence tying reticulated polyurethane specifically to medicament loading/release, that could rebut the routine‑selection theory. No such evidence is in the record I have; whether it exists in prosecution files is a factual question for Patent Center.

6. The one genuinely contested limitation: "released … by the application of heat"

This is where I want to be candid rather than persuasive.

What I could not find. Among the verified references in the Citations (94) block, none squarely discloses a medicament whose release into a wound volume is triggered by applied heat. Sene introduces antiseptic agents through slits; Checconi provides a "layer of disinfectant material"; Lubens provides an anesthetic pad enhanced by occlusion and pressure. Those are release teachings, not heat‑triggered release teachings. US 4,947,842's title ("first and second modalities") is suggestive but unverified.

How a challenger would bridge it (three independent routes; any one suffices):

1. Combination of known elements with predictable result. Heat a closed volume (Golden, US 4,572,188, US 4,277,255) that contains an agent‑bearing dressing (Sene, Checconi, Lubens). Warming a mass of impregnated foam necessarily increases the vapour pressure and diffusion of volatile/releasable agents into the enclosed headspace. The recited function is the inherent result of the combination, and inherency is sufficient for anticipation and a fortiori for obviousness. Under § 112 ¶ 6, the prior art need only perform the function; it need not describe it as a design intent.
2. Express teaching in Lubens. Lubens teaches that release/penetration is a controllable variable affected by the occlusive environment and by pressure on the dressing. A skilled artisan seeking to control the dose and timing of an agent delivered into a closed treatment volume has an express reason from Lubens to manipulate the dressing's physical environment — and Golden supplies an obvious, available environmental variable: temperature.
3. "Obvious to try" is not the theory; the number of options is not vast. Under KSR, the challenger should argue that the combination is a finite, identified set of known techniques (heat the volume, or don't; deliver agent, and let it elute passively) with an expected outcome — not an unbounded search. A patentee will argue KSR's caution against "obvious to try" where "prior art gives no direction." The strength of the patentee's counter depends entirely on whether any cited reference actually teaches away from heating a medicament‑bearing dressing (e.g., on heat‑degradation grounds). I found no express teaching away in the verified references, but I also did not conduct an exhaustive search of the full text of all 94 citations.

Practical litigation note. Because claim 1's final limitation is a means clause with a functional recitation, the § 103 fight and the § 112(f) construction fight are the same fight. If the disclosed structure is "foam impregnated with any of antibiotic/antifungal/antimicrobial/deodorant/nitric‑oxide material, released on heating," the challenger should map that structure (and equivalents) into the Checconi/Golden/Lubens combination; a narrow Williamson construction actually helps the challenger by shrinking the distance between claim scope and the art.

7. Method claims 12–18 and 19–25

Method claims are generally easier to invalidate where the apparatus is old and the steps describe its ordinary use.

Claim 12: attaching the device over the treatment area (Checconi, Sene, Lubens — all describe applying the dressing so the volume encloses the wound); "flexing the transition portion to accommodate patient motion" (Checconi claims 5/6/8 and Sene's displaceable tongues; the '046 specification itself concedes the purpose is the ordinary use of a compliant dressing); heating the treatment volume (Golden; US 4,572,188); releasing the medicament in response to heat (the inherent result, §6 above). Every step is either disclosed as a step or is the inherent consequence of the disclosed structure. This looks like In re "the method of using a known device for its intended purpose."

Claim 13 (transparent cover + viewing) — Sene's dome is expressly "translucent"; the '046's own figure description calls the wound cover "transparent … [which] allows one to see the wound treatment area." A method step of looking through a transparent dressing is a natural and obvious result, not a patentable step.

Claim 14 (cover is a mapping grid; tracking) — same weakness as claim 11.

Claim 15 (cover is a passive heater with a reflective surface) — reflective heat‑management surfaces are conventional; the '046 itself describes the accessory as "a passive heater with a reflective surface facing the wound." The step "heating the treatment volume" is thereby supplied by reflection of body heat, an entirely predictable use.

Claim 16 (insert a mapping grid into the pocket; track) and claim 17 (insert a heater into the pocket; operate it) — Golden's pocket‑and‑insert teaching (§5, claim 7 above) maps directly onto the inserting steps.

Claim 18 (medicament from the recited group) — a closed genus of five well‑known wound agents. Selection within a disclosed genus with no asserted criticality is routine. This claim also imports the same "released by … heat" question as §6.

Claim 19–25 (second method set): the distinguishing phrase is attaching the device "over a treatment area, out of contact with the treatment area." Non‑contact attachment is the express object of Checconi ("avoids any contact with the wound") and of Sene's superelevated dome. Claim 19's "flexing a transition membrane" reads on Checconi's flexible/folded distancer‑plus‑plaster structure and on Sene's folded edges. Nothing in claims 19–25 adds a step not already covered by the claim 12 analysis.

Drafting irregularity to preserve (carried forward from the earlier section, and I confirm it on the claim text): claims 20–22 depend from claim 19 yet refer to "the cover," while claim 19 recites no cover. That is a defect in the claim text, not a validity cure — but note that if those dependent claims are held indefinite under § 112 ¶ 2 for lack of antecedent basis, the corresponding validity challenge becomes unnecessary for that subset. (My reading of the text; not an adjudicated construction.)

8. Rebuttals the patentee will raise, and how they hold up

9. Bottom line

Claims 1–10 and 12–25 are, in my assessment, vulnerable to a § 103 challenge on the prior art of record, with WO 1989/004158 (Checconi) as the lead reference in view of US 3,814,095 (Lubens) and US 4,961,761 (Golden) — and US 2,443,481 (Sene) + US 4,341,209 (Schaar) as a strong alternative base. The cited art is all § 102(b) art (critical date 1993‑11‑21), which removes the swear‑behind and § 103(c) escape routes, and the patent's own background section contains admissions that non‑contact wound coverings and wound heaters were both known. The structural limitations of claim 1 track Checconi's own claim set closely enough that the "bodily incorporation" defence is answerable.

The two genuine points of exposure on the other side are:

1. The heat‑triggered release limitation (claim 1(g), and its echoes in claims 12, 18, 19, 25). No verified reference in the Citations block discloses it as a deliberate feature. A challenger must win it on inherency plus the Lubens release‑rate teaching, or must find it in one of the unverified citations (US 4,947,842 is the obvious candidate to check). If the patentee can show the art taught away from heating a medicament‑bearing dressing, claim 1 survives on this limitation alone — and with it claims 12, 18, 19, and 25.
2. Claim 11 (mapping grid) — I could find no cited art for it; it is the strongest of the dependent claims on this record.

Verification steps before anyone relies on this analysis:

1. Pull the full text of the ten unverified citations, especially US 4,947,842, US 4,277,255, US 4,392,816 (Spangler), US 4,572,188 (Augustine), and the vaccination‑shield line (US 697,637; US 720,812). Use https://patents.google.com/ and https://ppubs.uspto.gov/pubwebapp/ for the printed specs.
2. Confirm the effective filing date for the claims by checking whether every claim limitation, including the heat‑release limitation, is supported by the 1994‑11‑21 application (Ser. No. 08/342,741) — a written‑description gap would push the critical date to 2001/2002 and change the entire prior‑art calculus. This is the single highest‑leverage check.
3. Resolve the § 103(c) question for the 1992‑priority Augustine family (common ownership at the time of invention) via USPTO assignment records — https://assignment.uspto.gov/patent/.
4. Obtain the prosecution histories of application 10/254,175 and its parent 09/815,530 from Patent Center (https://patentcenter.uspto.gov/) to see which of the cited references the examiner actually relied on and which were merely listed — that tells you where the real art of record lies, and whether any of my proposed combinations was considered and overcome.
5. Re‑confirm the expiration/term record before treating any of this as a live controversy; as the earlier sections of this file note, the Google Patents status line (Expired – Fee Related; adjusted expiration 2016‑10‑01) and the § 286 six‑year damages lookback together make the practical stakes of this validity analysis very different from those of an in‑force patent. The exact derivation of the 2016‑10‑01 date (terminal disclaimer vs. statutory term vs. PTA adjustment) is not something I can verify from the page data — flag it as unresolved.

Confidence levels: Claim‑1 limitation mapping to Checconi/Sene/Lubens/Golden/Schaar — moderate‑to‑high for the verified references (I read their specifications and, for Checconi and Sene, their claims directly). The heat‑triggered‑release analysis — moderate; it is an argument, not a finding, and rests on inherency plus the absence of a teaching away, which I could not verify exhaustively. Claim 11 mapping grid — low; no supporting art identified. Title‑level references (shield line, US 4,947,842, US 4,277,255, US 4,392,816) — low; verify before use.